Although we cannot rule out the potential involvement of other genes in ARID2 loss-mediated LUAD progression, our findings of the superior efficacy of HSP70 inhibitors in ARID2-deficient tumors clearly support the functional importance of HSPA1A in this setting and provide a potential new therapeutic strategy for clinical management of lung cancer with this subtype. This evidence concerns the gene HSPA1A and lung carcinoma.